Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
Related Articles
- Update on H.R. 8875 “Improving Home Dialysis Act of 2026.” Posted 07-16-2026
- Stickman Industries Offers Many Products for Home Dialysis Patients Posted 07-16-2026
- Who Qualifies for Home Dialysis? Posted 07-16-2026
- NxStage’s ICan Tool Can Help HD Patients Learn to Self-cannulate Posted 07-16-2026